Multiple Sclerosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Sclerosis stocks.

Multiple Sclerosis Stocks Recent News

Date Stock Title
Nov 1 SNY Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
Nov 1 TEVA Teva long-acting olanzapine shows improvements in schizophrenia patients
Nov 1 TEVA Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Nov 1 TEVA Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
Nov 1 SNY Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Nov 1 TEVA Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 1 TEVA EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
Nov 1 SNY Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ...
Oct 31 MYO Myomo Announces First Private Payer Contracts for MyoPro In-network Coverage
Oct 31 TEVA Teva fined $500M by EU for disparaging rival MS drug (update)
Oct 31 IONS Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Oct 31 SNY REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
Oct 31 TEVA EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug
Oct 31 TEVA Teva Fined Around $500 Million by EU Over MS Drug Competition Concerns
Oct 31 TEVA Teva Statement on European Commission Decision; Company to Appeal
Oct 30 MYO Myomo to Report Third Quarter Financial Results on November 6, 2024
Oct 30 SNY Q3 2024 BioMarin Pharmaceutical Inc Earnings Call
Oct 30 IONS Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Oct 29 CGEN Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Oct 28 SNY Beyfortus® immunization to protect infants from RSV has begun
Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments, despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of an unaffected population.Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by Jean-Martin Charcot. The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord. A number of new treatments and diagnostic methods are under development.

Browse All Tags